FDA-approved
Heart & blood
Echinocandins
Evidence
FDA approved
Class
Cyclic lipopeptide antifungals
KEY TAKEAWAY
Echinocandins are a class of antifungal drugs built on cyclic lipopeptides. Caspofungin, micafungin, anidulafungin and rezafungin are approved in the United States. Caspofungin (Cancidas), micafungin (Mycamine) and anidulafungin (Eraxis) are FDA-approved for serious fungal infections. Rezafungin (Rezzayo) was added in 2023.
Written by the Veylo editorial team · Updated
November 2026
What it is
Cyclic lipopeptide antifungals
Approved for
Invasive Candida and Aspergillus infections
Key fact
Caspofungin (Cancidas), micafungin (Mycamine) and anidulafungin (Eraxis) are FDA-approved for serious fungal infections. Rezafungin (Rezzayo) was added in 2023.
Route
Intravenous infusion
Evidence strength
FDA approved
Echinocandins are a class of antifungal drugs built on cyclic lipopeptides. Caspofungin, micafungin, anidulafungin and rezafungin are approved in the United States.
They block the enzyme that makes beta-glucan, a building block of the fungal cell wall.
Caspofungin (Cancidas), micafungin (Mycamine) and anidulafungin (Eraxis) are FDA-approved for serious fungal infections. Rezafungin (Rezzayo) was added in 2023.
Invasive Candida and Aspergillus infections.
Liver enzyme increases, infusion reactions and low potassium can occur. They are generally well tolerated.
U.S. FDA prescribing information for Echinocandins. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.